Are human platelet alloantigens (HPA) minor transplantation antigens in clinical bone marrow transplantation?

Bone Marrow Transplantation

Volumn 31, Issue 6, 2003, Pages 497-506

  Rozman P ^a   Karas, M ^b   Kosir A ^a   Labar, B ^c   Madrigal, A ^d   Middleton, D ^e,e   Navarrete, C ^f   Oudshoorn, M ^g   Schennach, H ^h   Vitek, A ^l   Bohinjec, M ^a   Dovc T ^a   Ficko, T ^a   Vidan Jeras, B ^a   Jeras, M ^a   Pretnar, J ⁱ   Jazbec, J ⁱ   van Walraven, A M ^g   Jindra P ^b   Karlachova, I ^l   Schmarda, H ^h   Nachbaur, D ^j   Kastelan A ^c   Pisk, M ^c   Ceuk E ^c   Golubic B ^c   Ivankovic Z ^c   McMullin, M F ^k   Sage, D ^f   Pay, A ^d   more..

^a BLOOD TRANSFUSION CENTRE OF SLOVENIA   (Slovenia)

^b CHARLES UNIVERSITY   (Czech Republic)

^c KBC Zagreb   (Croatia)

^d ANTHONY NOLAN RESEARCH INSTITUTE   (United Kingdom)

^e BELFAST CITY HOSPITAL   (United Kingdom)

^f North London Blood Transfusion Centre   (United Kingdom)

^g Europdonor Foundation   (Netherlands)

^h UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

ⁱ UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

^j INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^k QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^l NONE

more..

Author keywords

Glycoproeteins; Graft versus host disease; Haematopoietic recovery; Histocompatibility; Polymorphism

Indexed keywords

ALLOANTIGEN; ANTINEOPLASTIC AGENT; EPITOPE; HLA ANTIGEN; MINOR HISTOCOMPATIBILITY ANTIGEN; THROMBOCYTE ANTIGEN; TRANSPLANTATION ANTIGEN;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; AGE; ALLOTYPE; APLASTIC ANEMIA; BONE MARROW TRANSPLANTATION; CANCER RADIOTHERAPY; CHRONIC MYELOID LEUKEMIA; CLINICAL OBSERVATION; CLINICAL PROTOCOL; CONTROLLED STUDY; DONOR; FEMALE; GENOTYPE; GRAFT SURVIVAL; GRAFT VERSUS HOST REACTION; HEMATOPOIESIS; HISTOCOMPATIBILITY; HLA MATCHING; HODGKIN DISEASE; HUMAN; HYPOTHESIS; INCIDENCE; MAJOR CLINICAL STUDY; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; RECIPIENT; RELAPSE; REVIEW; SIBLING; TREATMENT OUTCOME;

ADULT; ANTIGENS, HUMAN PLATELET; BLOOD PLATELETS; BONE MARROW TRANSPLANTATION; FEMALE; GRAFT SURVIVAL; GRAFT VS HOST DISEASE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MINOR HISTOCOMPATIBILITY ANTIGENS; POLYMORPHISM, GENETIC; RECURRENCE; SURVIVAL RATE;

EID: 0242669387     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1703854     Document Type: Review

References (51)

1. Goulmy E, Schipper R, Pool J et al. Mismatches of minor histocompatibility antigens between HLA-identical donors and recipients and the development of graft-versus-host disease after bone marrow transplantation. N Engl J Med 1996; 334: 281-285.
2. Gratwohl A, Hermans J. Outcome of blood and marrow transplants. In: Apperley J, Gluckman E, Gratwohl A (eds). Blood and Marrow Transplantation. The EBMT Handbook. European School of Haematology and European Blood and Marrow Transplantation: Paris, 2000, pp 110-118.
3. Atkinson K, Horowitz MM, Gale RP et al. Risk factors for chronic graft-versus-host disease after HLA-identical sibling bone marrow transplantation. Blood 1990; 75: 2459-2464.
4. Tay GK, Witt CS, Christiansen FT et al. Matching for MHC haplotypes results in improved survival following unrelated bone marrow transplantation. Bone Marrow Transplant 1995; 15: 381-385.
5. Roopenian DC. What are minor histocompatibility loci? A new look at an old question. Immunol Today 1992; 13: 7-10.
6. Niederwieser D, Grassegger A, Auböck J et al. Correlation of minor histocompatibility antigen-specific cytotoxic T lymphocytes with graft-versus-host disease status and analyses of tissue distribution of their target antigens. Blood 1993; 81: 2200-2208.
7. Goulmy E. Human minor histocompatibility antigens. Curr Opin Immunol 1996; 8: 75-81.
8. Behar E, Chao NJ, Hiraki DD, Krishnaswamy S et al. Polymorphism of adhesion molecule CD31 and its role in acute graft-versus-host disease. N Engl J Med 1996; 334: 286-291.
9. Nichols WC, Antin JH, Lunetta KL et al. Polymorphism of adhesion molecule CD31 is not a significant risk factor for graft-versus-host disease. Blood 1996; 88: 4429-4434.
10. Maruya E, Saji H, Seki S et al. Evidence that CD31, CD49b, and CD62L are immunodominant minor histocompatibility antigens in HLA identical sibling bone marrow transplants. Blood 1998; 92: 2169-2176.
11. Goulmy E. Human minor histocompatibility antigens: new concepts for marrow transplantation and adoptive immunotherapy. Immunol Rev 1997; 157: 125-140.
12. Perreault C, Decary F, Brochu S et al. Minor histocompatibility antigens. Blood 1990; 76: 1269-1280.
13. Simpson E. Minor transplantation antigens: animal models for human host-versus-graft, graft-versus-host, and graft-versus-leukemia reactions. Transplantation 1998; 65: 611-6.
14. Simpson E, Roopenian D, Goulmy E. Much ado about minor histocompatibility antigens. Immunol Today 1998; 19: 108-112.
15. Simpson E, Scott D, James E et al. Minor H antigens: genes and peptides. Eur J Immunogenet 2001; 28: 505-513.
16. von dem Borne AEGK, De Haas M, Simcek S et al. Platelet and neutrophil alloantigens in clinical medicine. Vox Sang 1996; 70: 34-40.
17. Lucas GF, Metcalfe P. Platelet and granulocyte glycoprotein polymorphisms. Transfus Med 2000; 10: 157-174.
18. Santoso S. Clinical impact of platelet glycoprotein polymorphism. Vox Sang 2000; 78(Suppl. 2): 121-124.
19. Santoso S. Platelet polymorphisms in thrombotic disorders. Transfusion Clin Biolo 2001; 8: 261-266.
20. Kieffer N, Phillips DR. Platelet membrane glycoproteins: functions in cellular interactions. Annu Rev Cell Biol 1990; 6: 329-357.
21. Pigott R, Power C. The Adhesion Molecule Facts Book. Academic Press: London, 1993.
22. Giltay JC, Brinkman HJ, dem Borne AE, van Mourik JA. Expression of the alloantigen Zwa (or P1A1) on human vascular smooth muscle cells and foreskin fibroblasts: a study on normal individuals and a patient with Glanzmann's thrombasthenia. Blood 1989; 74: 965-970.
23. Helfrich MH, Nesbitt SA, Horton MA. Integrins on rat osteoclasts: characterization of two monoclonal antibodies (F4 and F11) to rat beta 3. J Bone Miner Res 1992; 7: 345-351.
24. Nesbitt S, Nesbit A, Helfrich M, Horton M. Biochemical characterization of human osteoclast integrins. Osteoclasts express alpha v beta 3, alpha 2 beta 1, and alpha v beta 1 integrins. J Biol Chem 1993; 268: 16737-16745.
25. Demaziere A, Athanasou NA. Adhesion receptors of intimal and subintimal cells of the normal synovial membrane. J Pathol 1992; 168: 209-215.
26. Martín-Villa JM, Ferre-López S, López-Suárez JC et al. Cell surface phenotype and ultramicroscopic analysis of purified human enterocytes: a possible antigen-presenting cell in the intestine. Tissue Antigens 1997; 50: 586-592.
27. Jaskiewicz K, Chasen MR. Differential expression of transforming growth factor alpha, adhesions molecules and integrins in primary, metastatic liver tumors and in liver cirrhosis. Anticancer Res 1995; 15: 559-562.
28. Rajagopalan V, Essex DW, Shapiro SS, Konkle BA. Tumor necrosis factor-alpha modulation of glycoprotein Ib alpha expression in human endothelial and erythroleukemia cells. Blood 1992; 80: 153-161.
29. Barclay AN, Brown MH, Law ASK et al. The Leucocyte Antigen Facts Book, 2nd edn. Academic Press: San Diego, 1997.
30. Giltay JC, Brinkman HJ, Modderman PW et al. Human vascular endothelial cells express a membrane protein complex immunochemically indistinguishable from the platelet VLA-2 (glycoprotein Ia-IIa) complex. Blood 1989; 73: 1235-1241.
31. Shaw S, Luce GG, Gilks WR et al. Leucocyte differentiation antigen database. In: Schlossman SF, Boumsell L, Gilks W, Harlan JM, Kishimoto T, Morimoto C et al., (eds). Leucocyte Typing V. Oxford University Press: New York, 1995, pp 16-198.
32. Blanchette VS, Rand ML. Platelet disorders in newborn infants: diagnosis and management. Semin Perinatol 1997; 21: 53-62.
33. Kekomäki S, Salmela K, Partanen J et al. Alloimmunization against platelet antigens in renal transplant patients with acute vascular rejection. Clin Transplant 1997; 11: 19-24.
34. Valentin N, Vergracht A, Bignon JD et al. HLA-DRw52a is involved in alloimmunization against PL-A1 antigen. Hum Immunol 1990; 27: 73-79.
35. Mueller-Eckhardt C, Kiefel V, Kroll H, Mueller-Eckhardt G. HLA-DRw6, a new immune response marker for immunization against the platelet alloantigen Bra. Vox Sang 1989; 57: 90-91.
36. Kekomäki S, Kyllonen L, Salmela K et al. Platelet-specific alloantigens in cadaveric renal transplantation. A prospective study. Effect of HPA-5b mismatch in acute vascular rejection of renal allografts. Tissue Antigens 2001; 57: 154-157.
37. Juji T, Saji H, Satake M, Tokunaga K. Typing for human platelet alloantigens. Rev Immunogenet 1999; 1: 239-254.
38. Balduini CL, Noris P, Giorgiani G et al. Incompatibility for CD31 and human platelet antigens and acute graft-versus-host disease after bone marrow transplantation. Br J Haematol 1999; 106: 723-729.
39. Hurley CK, Wade JA, Oudshoorn M et al. A special report: histocompatibility testing guidelines for hematopoietic stem cell transplantation using volunteer donors. Quality Assurance and Donor Registries Working Groups of the World Marrow Donor Association. Hum Immunol 1999; 60: 347-360.
40. Rožman P, Drabbels J, Schipper RF et al. Genotyping for human platelet-specific antigens HPA-1, -2, -3, -4 and -5 in the Slovenian population reveals a slightly increased frequency of HPA-1b and HPA-2b as compared to other European populations. Eur J Immunogenet 1999; 26: 265-269.
41. European Group for Blood and Marrow Transplantation. MED A-B forms for registration of allogeneic or autologous stem cells transplantation. European Group for Blood and Marrow Transplantation (eds). EBMT, 1998. 2000, pp 1-71. EBMT. http://www.ebmt.org/EBMT/DOCU/MANUALS/PAPERFOR.PDF.
42. European Group for Blood and Marrow Transplantation. MED A - FORM. DEFINITIONS and INSTRUCTIONS. European Group for Blood and Marrow Transplantation (eds). EBMT. 2001, pp 1-38. EBMT. http://www.ebmt.org/4Registry/Registry_docs/definitions.pdf.
43. Dreger P, Gluckman E, Schmitz N. Source of haemopoietic stem cells. In: Apperley J, Gluckman E, Gratwohl A (eds). Blood and Marrow Transplantation. The EBMT Handbook. European School of Haematology and European Blood and Marrow Transplantation: Paris, 2000, pp 68-90.
44. Labopin M. Statistical guidelines for research in EBMT. European Group for Blood and Marrow Transplantation 2000, 1-5. EBMT: http://www.ebmt.org/1WhatisEBMT/Op_Manual/OPMAN_StatGuidelines.pdf.
45. Devergie A, Janin A. Graft versus host disease. In: Apperley J, Gluckman E, Gratwohl A (eds). Blood and Marrow Transplantation. The EBMT Handbook. European School of Haematology and European Blood and Marrow Transplantation: Paris, 2000, pp 134-151.
46. Ferrara JL, Deeg HJ. Graft-versus-host disease. N Engl J Med 1991; 324: 667-674.
47. Juji T, Watanabe Y, Ishikawa Y et al. Human platelet alloantigen (HPA)-5a/b mismatch decreases disease-free survival in unrelated bone marrow transplantation (In Process Citation). Tissue Antigens 1999; 54: 229-234.
48. Dolstra H, Fredrix H, Maas F et al. A human minor histocompatibility antigen specific for B cell acute lymphoblastic leukemia. J Exp Med 1999; 189: 301-308.
49. Mutis T, Verdijk R, Schrama E et al. Feasibility of immunotherapy of relapsed leukemia with ex vivo-generated cytotoxic T lymphocytes specific for hematopoietic system-restricted minor histocompatibility antigens. Blood 1999; 93: 2336-2341.
50. Storb RF, Champlin R, Riddell SR et al. Non-myeloablative transplants for malignant disease. Hematology (Am Soc Hematol Educ Program) 2001; 1: 375-391.
51. Gjertson GW, Lee SH. HLA-A/B and -DRB1/DQB1 allele-level haplotype frequencies. In: Gjertson DW, Terasaki PI (eds). HLA 1998. American Society for Histocompatibility and Immunogenetics: Lenexa, Kansas, 1998, pp 365-450.